Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

10873	Companies
236404	Keywords
165301	Articles
126786	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

PRESS RELEASE

published on 09/15/2025 at 16:45, 11 months 8 days ago

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Protagonist Therapeutics to present Phase 2b ANTHEM-UC study data on targeted oral peptide icotrokinra at UEGW Week 2025 in Berlin. Company focuses on advanced therapies in ulcerative colitis

Ulcerative Colitis Protagonist Therapeutics Icotrokinra Phase 2b ANTHEM-UC Study UEGW Week 2025
BRIEF

published on 09/11/2025 at 14:05, 11 months 13 days ago

Un acteur majeur sollicite l'approbation de l'EMA pour l'icotrokinra dans le traitement du psoriasis

Essais Cliniques Icotrokinra Psoriasis En Plaques Efficacité Du Traitement Demande D'admission À L'EMA
BRIEF

published on 09/11/2025 at 14:05, 11 months 13 days ago

Protagonist Seeks EMA Approval for Icotrokinra in Psoriasis

Clinical Trials Plaque Psoriasis Icotrokinra Treatment Efficacy EMA Application
PRESS RELEASE

published on 09/11/2025 at 14:00, 11 months 13 days ago

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Protagonist Therapeutics submits application to EMA for first approval of icotrokinra, an investigational targeted oral peptide blocking IL-23 receptor in plaque psoriasis treatment

Protagonist Therapeutics Plaque Psoriasis Treatment IL-23 Receptor Icoktrokinra EMA Submission
BRIEF

published on 08/26/2025 at 22:10, 11 months 28 days ago

Protagonist Therapeutics Engages in Key Investment Conferences

Clinical Trials Protagonist Therapeutics Investment Conferences Biopharmaceutical Development Icotrokinra And Rusfertide
BRIEF

published on 08/26/2025 at 22:10, 11 months 28 days ago

Protagonist Therapeutics participe à des conférences d'investissement clés

Essais Cliniques Thérapeutique Protagoniste Conférences D'investissement Développement Biopharmaceutique Icotrokinra Et Rusfertide
PRESS RELEASE

published on 08/26/2025 at 22:05, 11 months 28 days ago

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Protagonist Therapeutics announced CEO's participation in investment bank conferences in September. Company's advanced Phase 3 clinical development and future plans highlighted

Protagonist Therapeutics Phase 3 Clinical Development NDA Submission Investment Bank Conferences Drug Discovery Programs
BRIEF

published on 08/25/2025 at 13:05, 11 months 30 days ago

Le Rusfertide de Protagonist Therapeutics reçoit la désignation de thérapie révolutionnaire de la FDA

Rusfertide Thérapeutique Protagoniste Polyglobulie Vraie Thérapie Révolutionnaire Phase 3 VÉRIFIER
BRIEF

published on 08/25/2025 at 13:05, 11 months 30 days ago

Protagonist Therapeutics' Rusfertide Receives FDA Breakthrough Therapy Designation

Protagonist Therapeutics Rusfertide Polycythemia Vera Breakthrough Therapy Phase 3 VERIFY
PRESS RELEASE

published on 08/25/2025 at 13:00, 11 months 30 days ago

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Protagonist Therapeutics' rusfertide granted Breakthrough Therapy Designation by the FDA for polycythemia vera, complementing Orphan Drug and Fast Track designations. NDA filing on track for Q4

FDA Protagonist Therapeutics Rusfertide Breakthrough Therapy Designation NDA Filing

Accesswire

Published on 08/24/2026 at 16:00, 41 minutes ago

Critical Elements - le programme de forage estival de 10 000 mètres À rose ouest continu de livrer des résultats positifs
Published on 08/24/2026 at 16:00, 41 minutes ago

Critical Elements' 10,000-Meter Summer Drill Program at Rose West Continues to Deliver Positive Results
Published on 08/24/2026 at 15:00, 1 hour 41 minutes ago

Silver Storm Announces Upsize of Non-Brokered Private Placement to $15.0 Million
Published on 08/24/2026 at 14:30, 2 hours 11 minutes ago

AIAI Holdings Commences Discussions with Messier 42 LLC Regarding Acquisition Opportunities
Published on 08/24/2026 at 13:45, 2 hours 56 minutes ago

Amarc Announces CAD$20 Million Private Placement Financing

View all ACCESSWIRE

EQS Group

Published on 08/24/2026 at 15:45, 56 minutes ago

EQS-Adhoc: QIAGEN N.V.: QIAGEN appoints Jonathan M. Pratt as Chief Executive Officer
Published on 08/24/2026 at 15:37, 1 hour 3 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Prologis, Inc.
Published on 08/24/2026 at 15:37, 1 hour 4 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DNO Iraq AS (a wholly owned subsidiary of DNO ASA)
Published on 08/24/2026 at 15:36, 1 hour 5 minutes ago

Form 8.3 - The Vanguard Group, Inc.: DCC plc
Published on 08/24/2026 at 15:36, 1 hour 5 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Beazley plc

Les Echos

Published on 08/24/2026 at 12:25, 4 hours 16 minutes ago

GUILLEMOT CORPORATION | Weekly report share buyback from August 17 to August 21 2026
Published on 08/24/2026 at 12:25, 4 hours 16 minutes ago

GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 17 au 21 août 2026
Published on 08/24/2026 at 11:58, 4 hours 43 minutes ago

Déclaration du nombre d'actions composant le capital social et du nombre total de droits de vote au 31 juillet 2026
Published on 08/24/2026 at 11:58, 4 hours 43 minutes ago

Statement about the number of shares composing the share capital and the number of voting rights as of July 31, 2026
Published on 08/21/2026 at 18:33, 2 days 22 hours ago

260821 BENETEAU Transaction sur actions propres

View all LES ECHOS COMFI WIRE